Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C40H63N15O13 |
Molecular Weight | 962.0209 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(O)=O)NC2=O)C(C)C
InChI
InChIKey=JXPWLIYXIWGWSA-CLBRJLNISA-N
InChI=1S/C40H63N15O13/c1-19(2)31-38(67)51-23(8-11-29(42)58)34(63)53-26(17-56)39(68)55-14-4-6-27(55)37(66)50-24(9-12-30(59)60)33(62)52-25(15-20-16-45-18-47-20)36(65)49-22(7-10-28(41)57)32(61)48-21(35(64)54-31)5-3-13-46-40(43)44/h16,18-19,21-27,31,56H,3-15,17H2,1-2H3,(H2,41,57)(H2,42,58)(H,45,47)(H,48,61)(H,49,65)(H,50,66)(H,51,67)(H,52,62)(H,53,63)(H,54,64)(H,59,60)(H4,43,44,46)/t21-,22-,23-,24-,25-,26-,27-,31-/m0/s1
Livoletide (AZP-531) is an analog of unacylated ghrelin, a naturally occurring hormone that is thought to counteract the effects of acylated ghrelin. The drug was designed to improve glycaemic control and reduce weight. Livoletide participated in pivotal phase 2b/3 clinical study for the treatment of Prader-Willi syndrome. In addition, the drug was studied in patients with type 2 diabetes mellitus (T2D). Its pharmacokinetic profile, suitable for once daily dosing, and metabolic effects support further clinical development for T2D.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03790865
Daily subcutaneous injection of ~ 60 mcg/kg or 120 mcg/k for 3 month double-blind core period and 9 month open label extension period.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
603317
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000181117
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY | |||
|
9VHD7J6363
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY | |||
|
57341282
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY | |||
|
1088543-62-7
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY | |||
|
DB15188
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY | |||
|
C174590
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY | |||
|
10715
Created by
admin on Sat Dec 16 17:11:05 GMT 2023 , Edited by admin on Sat Dec 16 17:11:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY